Natco Pharma, a company in the Pharmaceuticals industry, reported revenue of ₹967 crore and net profit of ₹203 crore for the September 2026 quarter.
Natco Pharma (NSE: NATCOPHARM) closed at ₹814.30 on 20 Nov 2026, down 6.3% over the past year. Its market capitalisation is ₹15,974 crore and it trades at 19.3 times earnings.
NATCO Pharma Limited (NATCO) is a vertically integrated, research and development focused pharmaceutical company engaged in developing, manufacturing, and marketing complex products for niche therapeutic areas. NATCO has established its presence in all three business segments viz. finished dosage formulations (“FDF”), active pharmaceutical ingredients (“APIs”), Contract Manufacturing Business.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.